

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **Enttheon Biomedical Corp.** (“the “Issuer”).

Trading Symbol: **ENBI**

Number of Outstanding Listed Securities: **54,039,266**

Date: **June, 2021**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 10, the Issuer announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in the United States.

On June 16, the Issuer announce that the Issuer had entered into a definitive agreement dated June 15, 2021 with Lobo Genetics Inc. (“Lobo”), and 13089363 Canada Inc., a wholly-owned subsidiary of Issuer. Pursuant to the Agreement, the Issuer and Lobo will combine their respective businesses by way of a “three-cornered” amalgamation in accordance with section 185 of the *Canada Business Corporations Act* (the “CBCA”) (the “Transaction”).

On June 17, the Issuer announced that it had signed a referral agreement with Silo Wellness Inc. (“Silo”) to help drive brand awareness of the Psychedelics Genetic Test kit, as well as empower guests at Silo Wellness’ retreats to make informed decisions through better access to information about themselves.

On June 22, the Issuer announced it had entered into an agreement with 3W Wellness Inc. (“Third Wave”) to help drive brand awareness of the company’s Psychedelics Genetic Test kit, developed and commercialized by HaluGen.

2. Provide a general overview and discussion of the activities of management.

Management has been focused on developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

This section is not applicable to the Issuer.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This section is not applicable to the Issuer.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

As set out in Section 1, the Issuer entered into new business relationships with Silo, Third Wave and Lobo. All are arm's length to the Issuer.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

This section is not applicable to the Issuer.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

As set out in Section 1, pursuant to the Transaction with Lobo, the Issuer shall acquire all shares issued and outstanding in Lobo in consideration of an aggregate 5,000,000 common shares in the capital of the Issuer.

In addition, the Issuer will issue 9,603 incentive stock options to the holders of outstanding stock options of Lobo in exchange for the exchange or conversion of the Lobo stock options and may issue up to 46,944 common share purchase warrants to the holders of the outstanding common shares purchase warrants of Lobo in exchange for the conversion, exchange or cancellation of the Lobo warrants.

Lobo brings a highly experienced and specialized team of technology experts in the fields of genetics, diagnostics, data and analytics, as well as a fully operational 5,000 sq. ft. genetics research and development and testing facility located in Mississauga, Ontario. Lobo also has various existing distribution and partner relationships both domestically and internationally that are a strategic fit with the Issuer's goal of expanding its personalized psychedelics platform globally.

In addition to the psychedelics genetic test that Lobo has developed in partnership with HaluGen, Lobo offers a cannabis genetic test that can provided personalized insights into an individual's cannabis metabolism, risk and impairment, including: (a) ability to metabolize THC and CBD; (b) increased acute psychotomimetic effects and long-term risk of cannabis-induced psychosis; and (c) neurocognitive impairment including short-term memory loss.

8. Describe the acquisition of new customers or loss of customers.

This section is not applicable to the Issuer.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

This section is not applicable to the Issuer.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This section is not applicable to the Issuer.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This section is not applicable to the Issuer.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This section is not applicable to the Issuer.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

This section is not applicable to the Issuer.

14. Provide details of any securities issued and options or warrants granted.

This section is not applicable to the Issuer.

15. Provide details of any loans to or by Related Persons.

This section is not applicable to the Issuer.

16. Provide details of any changes in directors, officers or committee members.

This section is not applicable to the Issuer.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

This section is not applicable to the Issuer.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: June 7, 2021

Brandon Schwabe
Name of Director or Senior Officer

"Brandon Schwabe"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer Entheon Biomedical Corp.	For Month End June	Date of Report YY/MM/D 21/07/07
Issuer Address 211-3030 Lincoln Avenue		
City/Province/Postal Code Coquitlam, BC, V3B 6B4	Issuer Fax No. n/a	Issuer Telephone No. (604) 562-3932
Contact Name Timothy Ko	Contact Position CEO	Contact Telephone No. (604) 562-3932
Contact Email Address: timothy@entheonbiomedical.com	Web Site Address https://entheonbiomedical.com	